The role of herpesviruses in ocular infections

Virus Adaptation and Treatment

Volumn 2, Issue 1, 2010, Pages 115-123

  Farooq, Asim V ^a   Shah, Arpeet ^a   Shukla, Deepak ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Antivirals; Epidemiology; Ocular herpes; Ocular lymphomas; Seroprevalence; Viral entry; Viral vaccine

Indexed keywords

ACICLOVIR; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; CYTOMEGALOVIRUS VACCINE; FAMCICLOVIR; GANCICLOVIR; HERPES SIMPLEX VACCINE; LIVE VACCINE; NUCLEOSIDE ANALOG; STEROID; TRIFLURIDINE; VALACICLOVIR; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE;

ARTICLE; BLINDNESS; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; EPIDEMIC; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EYE CANCER; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HERPETIC STOMATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INFECTION SENSITIVITY; LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; RECURRENT VIRUS INFECTION; SEROPREVALENCE; SKIN PAIN; VARICELLA ZOSTER VIRUS; VIRAL EYE INFECTION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 77957305511     PISSN: None     EISSN: 11791624     Source Type: Book Series    
DOI: 10.2147/VAAT.S9500     Document Type: Article

References (64)

1. Kaye S, Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res. 2006;25(4):355-380.
2. Steiner I. Human herpes viruses latent infection in the nervous system. Immunol Rev. 1996;152:157-173.
3. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity. 2008;41(4):298-328.
4. Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol. 2008;197(2):65-73.
5. Caserta MT, Mock DJ, Dewhurst S. Human herpes virus 6. Clin Infect Dis. 2001;33(6):829-833.
6. De Araujo T, Berman B, Weinstein A. Human herpes viruses 6 and 7. Dermatol Clin. 2002;20(2):301-306.
7. Black JB, Pellet PE. Human herpes virus 7. Rev Med Virol. 1999; 9(4):245-262.
8. Verma SC, Robertson ES. Molecular biology and pathogenesis of Kaposi sarcoma-associated herpes virus. FEMS Microbiol Lett. 2003;222(2):155-163.
9. Pantry SN, Medveczky PG. Epigenetic regulation of Kaposi's sarcoma-associated herpes virus replication. Semin Cancer Biol. 2009;19(3):153-157.
10. Zwaagstra JC, Ghiasi H, Nesburn AB, Wechsler SL. Identification of a major regulatory sequence in the latency associated transcript (LAT) promoter of herpes simplex virus type 1 (HSV-1). Virology. 1991:182(1):287-297.
11. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964-973.
12. Hill JM, Ball MJ, Neumann DM, et al. The high prevalence of herpes simplex virus type 1 DNA in human trigeminal ganglia is not a function of age or gender. J Virology. 2008;82(16):8230-8234.
13. Kaufman HE, Azcuy AM, Varnell ED, et al. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci. 2005;46(1):241-247.
14. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. 2004;11(1):24A-35A.
15. Malkin J. Epidemiology of genital herpes simplex virus infection in developed countries. Herpes. 2004;11 Suppl 1:2a-23a.
16. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605): 2127-2137.
17. Langenberg AG, Correy L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. NEJM. 1999;341(19):1432-1438.
18. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis. 2003;30(10):797-800.
19. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3): 361-381.
20. Liesegang TJ. Herpes Zoster Ophthalmicus: Natural History, Risk Factors, Clinical Presentation, and Morbidity. Ophthalmology. 2008;115(2):S3-S12.
21. Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27(2):159-176.
22. Reynolds MA, Chaves SS, Harpaz R, et al. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis. 2008;197 Suppl 2:S224-S227.
23. Cannon MJ. Congenital Cytomegalovirus Epidemiology and Awareness. J Clin Virol. 2009;46 Suppl 4:S6-S10.
24. Boppana SB, Fowler KB, Pass RF, et al. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J Pediatr. 2005;146(6):817-823.
25. Slobod KS, Sandlund JT, Spiegel PH, et al. Molecular Evidence of Ocular Epstein-Barr Virus Infection. Clin Infect Dis. 2000;31(1): 184-188.
26. Knickelbein JE, Khanna KM, Yee MB, et al. Noncytotoxic lytic granulemediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science. 2008;322(5899):268-271.
27. Ghiasi H, Cai S, Perng GC, et al. Both CD4+ and CD8+ T-cells are involved in protection against HSV-1 induced corneal scarring. Br J Ophthalmol. 2000;84(4):408-412.
28. Lilley CE, Carson CT, Muotri AR, et al. DNA repair proteins affect the lifecycle of herpes simplex virus 1. Proc Natl Acad Sci. 2005; 102(16):5844-5849.
29. Akhtar J, Tiwari V, Oh M-J, et al. HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry into human conjunctival epithelium. Invest Ophthalmol Vis Sci. 2008;49(9): 4026-4035.
30. Tiwari V, Shukla SY, Yue BY, Shukla D. Herpes simplex virus type 2 entry into cultured human corneal fibroblasts is mediated by herpes virus entry mediator. J Gen Virol. 2007;88(8):2106-2010.
31. Tiwari V, Oh MJ, Kovacs M, et al. Role for nectin-1 in herpes simplex virus 1 entry and spread in human retinal pigment epithelial cells. FEBS J. 2008;275(21):5272-5285.
32. Shukla SY, Singh YK, Shukla D. Role of nectin-1, HVEM, and PILRalpha in HSV-2 entry into human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2009;50(6):2878-2887.
33. Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J. 2009;276(24): 7228-7236.
34. Valyi-Nagy T, Sheth V, Clement C, et al. Herpes simplex virus entry receptor nectin-1 is widely expressed in the murine eye. Curr Eye Res. 2004;29(4-5):303-309.
35. Liesgang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20:1-13.
36. Duker JS, Nielsen JC, Eagle RC, et al. Rapidly progressive acute retinal necrosis secondary to herpes simplex virus, type 1. Ophthalmology. 1990;97:1638-1643.
37. Smith LK, Kurz PA, Wilson DJ, et al. Two patients with the von Szily reaction: herpetic keratitis and contralateral retinal necrosis. Am J Ophthalmol. 2007;143:536-538.
38. Nussenblatt RB, Palestine AG. Acute retinal necrosis. In: Uveitis: Fundamentals and Clinical Practice. Year Book Medical Publishers. Chicago 1989;407-414.
39. Duker JS, Blumenkranz MS. Diagnosis and management of the acute retinal necrosis (ARN) syndrome. Surv Ophthalmol. 1991;35:327-343.
40. Inoda S, Wakakura M, Hirata J, et al. Stromal keratitis and anterior uveitis due to herpes simplex virus type-2 in a young child. Jpn J Ophthalmol. 2001;45(6):618-621.
41. Reichelt M, Zerboni L, Arvin AM. Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol. 2008;82(8):3971-3983.
42. Berarducci B, Sommer M, Zerboni L, Rajamani J, Arvin AM. Cellular and viral factors regulate the varicella-zoster virus gE promoter during viral replication. J Virol. 2007;81(19):10258-10267.
43. Hu AY, Strauss EC, Holland GN, et al. Late varicella-zoster virus dendriform keratitis in patients with histories of herpes zoster ophthalmicus. Am J Ophthalmol. 2010;149(2):214-220.
44. Pavan-Langston D, Dunkel EC. Ocular varicella-zoster virus infection in the guinea pig. A new in vivo model. Arch Ophthalmol. 1989;107(7): 1068-1072.
45. Milikan JC, Baarsma GS, Kuijpers RW, et al. Human ocular-derived virus-specific CD4+ T-cells control varicella zoster virus replication in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2009;50(2):743-751.
46. Hodge WG, Margolis TP. Herpes simplex virus keratitis among patients who are positive or negative for human immunodeficiency virus: an epidemiologic study. Ophthalmology. 1997;104(1):120-124.
47. Young TL, Robin JB, Holland GN, et al. Herpes simplex keratitis in patients with acquired immune deficiency syndrome. Ophthalmology. 1989;96(10):1476-1479.
48. Willoughby CE, Baker K, Kaye SB, et al. Epstein-Barr virus (types 1 and 2) in the tear film in Sjogren's syndrome and HIV infection. J Med Virol. 2002;68(3):378-383.
49. Saito I, Servenius B, Compton T. Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome. J Exp Med. 1989;169:2191-2198.
50. Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol. 2008;145(3):397-408.
51. Holland GN, Vaudaux JD, Jeng SM, et al; UCLA CMV Retinitis Study Group. Characteristics of untreated AIDS-related cytomegalovirus retinitis. I. Findings before the era of highly active antiretroviral therapy (1988 to 1994). Am J Ophthalmol. 2008;145(1):5-11.
52. Holland GN, Vaudaux JD, Shiramizu KM, et al; Southern California HIV/Eye Consortium. Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000). Am J Ophthalmol. 2008;145(1):12-22.
53. Thorne JE, Holbrook JT, Jabs DA, et al; Studies of Ocular Complications of AIDS Research Group. Effect of cytomegalovirus retinitis on the risk of visual acuity loss among patients with AIDS. Ophthalmology. 2007;114(3):591-598.
54. Zinkernagel MS, Petijean C, Fleming P, et al. In vivo imaging of ocular MCMV infection. Invest Ophthalmol Vis Sci. 2010;51:369-374.
55. Yamauchi Y, Suzuki J, Sakai J, et al. A case of hypertensive keratouveitis with endotheliitis associated with cytomegalovirus. Ocul Immunol Inflamm. 2007;15(5):399-401.
56. Méchaï F, Boutolleau D, Manceron V, et al. Human herpes virus 6-associated retrobulbar optic neuritis in an HIV-infected patient: response to anti-herpes virus therapy and long-term outcome. J Med Virol. 2007;79(7):931-934.
57. Moschettini D, Franceschini R, Vaccaro NM, et al. Human herpes virus-6B active infection associated with relapsing bilateral anterior optic neuritis. J Clin Virol. 2006 Dec;37(4):244-247.
58. Chan CC. Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc. 2003;101:275-292.
59. International Herpes Management Forum. The management of HSV-1 and ocular HSV diseases. Recommendations from the IHMF Management Strategies Workshop. IHMF 2002.
60. Matoba AY. Ocular disease associated with Epstein-Barr virus infection. Surv Ophthalmol. 1990;35(2):145-50.
61. Schrier RD, Song MK, Smith IL, et al. Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina. 2006;26(2):165-169.
62. Moss DJ, Suhrbier A, Elliott SL. Candidate vaccines for Epstein-Barr virus. BMJ. 1998;317(7156):423-424.
63. Griffith JF. Nervous system manifestations of cytomegalovirus (CMV) infection. Dev Med Child Neurol. 1971 Aug;13(4):520-522.
64. Dekker CL, Arvin AM. One step closer to a CMV vaccine. N Engl J Med. 2009;360(12):1250-1252.